New York lab robotics maker Opentrons has raised a $40 million Series E led by Avego to turn its 11,000+ robots into the place where AI designed experiments actually get run.
AI can dream up experiments faster than any lab can run them. Somebody still has to move the liquid.
Opentrons Labworks wants to be that somebody. The New York lab robotics company has raised a $40 million Series E led by healthcare investor Avego, with BroadOak Capital Partners also writing a check and existing backers SoftBank Vision Fund and Khosla Ventures staying in.
It’s a much smaller number than the last big one. In 2021, SoftBank led a $200 million Series C that valued Opentrons at $1.8 billion, a pandemic era round for a company whose robots were part of New York City’s COVID testing effort.

Five years on, the pitch is different.
Now it’s AI. Opentrons calls itself the “execution layer” for autonomous science: open, API driven robots that close the loop between a model suggesting an experiment and the bench where that experiment actually happens. Its argument goes like this, AI can generate experiments faster than labs can test them, so the physical lab has become the bottleneck, and whoever owns the robots in those labs gets to sit in the middle.
The main hardware is the Opentrons Flex, robots and AI systems meant to design, run and tweak experiments over and over, alongside the older OT-2. On the software side there’s OpentronsAI, which writes lab protocols from plain language requests, a no code Protocol Designer and a Python API. Earlier this year the company started using Nvidia’s Isaac and Cosmos platforms to generate training data for lab robots, and it teamed up with HighRes on what the two called the first agent to agent lab automation workflow.
The installed base is the real asset. More than 11,000 robots in over 80 countries. Inside 90 percent of the top 20 global pharma companies, and every top 20 U.S. research university.
The money goes to scaling robotics, software and data infrastructure, more work on AI run experiments, faster protocol development, and new markets and regions.

Recommended: Kodama Systems Raises $7M In Funding
CEO James Atwood, who took the top job in January after running the company’s global robotics business, says millions of scientists burn a big part of their day on manual work a robot could handle, and that handing that time back to discovery is the biggest opportunity science has. Opentrons first made automation accessible to any lab, as he tells it. Now its systems are built for AI to run experiments directly.
Avego managing partner James Flexner makes the same case from the money side. Every discovery an AI comes up with still has to be tested in a real lab, he said, and drug developers and AI companies alike are moving that work onto automated setups. He sees autonomous science converging on Opentrons’ platform.
Opentrons Labworks was founded in 2014. Sands Capital, Lerer Hippeau and Y Combinator are among its earlier backers.
Please email us your feedback and news tips at hello(at)dailycompanynews.com
